Press Coverage

Arteaus Therapeutics Sells Emgality Royalty for $260 Million (Royalty Pharma)

Royalty Pharma and Arteaus Therapeutics, a biotechnology development company co-founded by Atlas Venture and OrbiMed, announced today that Arteaus has sold its royalty interest on future global net sales of Eli Lilly and Company’s (NYSE: LLY) Emgality (galcanezumab), an anti-CGRP antibody for the prevention of migraine, to Royalty Pharma for $260 million.

Emgality was approved by the U.S. Food and Drug Administration on September 27, 2018 and by the European Medicines Agency on November 14, 2018. Emgality is an at-home, once monthly self-injection for the preventative treatment of episodic and chronic migraine in adults.

[...]

Wilmer Cutler Pickering Hale and Dorr LLP served as legal advisor to Arteaus. Jones Day and Maiwald served as legal advisors to Royalty Pharma.

This text is a press release from Royalty Pharma. The full text version of the article can be found here: https://www.royaltypharma.com/arteaus-therapeutics-sells-emgality-royalty-for-260-million/

Newsletter